Phakic intraocular lenses (IOLs), also known as implantable contact lenses (ICLs), are implantable contact lenses that are surgically inserted into the eye where they provide excellent quality of vision with predictable and stable results. The Visian ICL is the latest phakic intraocular lens to receive approval from the FDA for a wide range of myopic (nearsightedness) correction needs. This technology is adapted from the proven lens technology used for cataract surgery, and works by placing the Visian ICL in front of the natural lens inside the eye. The Visian ICL is made of an advanced material that is extremely biocompatible and provides superior optical performance.
________________________________________________________________________________________
_________________________________________________________________________________________
Read more about : Leg lengthening surgery success story in Iran
Read more about : Total knee replacement surgery success story in Iran
Read more about : Kidney transplant in Iran success story in Iran
Read more about : Cancer treatment success story in Iran
Read more about : Sex reassignment surgery success story
Read more about : Parkinson's disease treatment success story
Young patients who are unsuitable for laser vision correction are often offered PIOL implantation. This is because PIOLs can correct a wider range of spectacle prescriptions than laser vision correction, and may be a safer option if you have pre-existing cornea or eye surface problems.
PIOL implantation is performed using eye-drop anaesthetic supplemented by an injection in the back of your hand to relax you if required. Anaesthetic may also be washed around the back of the eye to prevent excessive eye movement. A spring clip holding the eyelids apart allows you to blink safely during surgery. In all forms of eye surgery, problems can occur during the operation or afterwards in the healing period. Problems can result in permanent, serious loss of vision (vision worse than the driving standard in the affected eye that cannot be corrected with glasses or contact lenses). More commonly, problems can be corrected with changes in medication or additional surgery. Typically, these additional operations feel like the original surgery and have a similar recovery period. Different types of PIOL have different associated risks. Your surgeon will ensure that you are given clear advice relevant to the lens type that is recommended. Loss of vision Permanent, serious loss of vision is very uncommon after ICL implantation.
Causes include damage to the nerve at the back of the eye caused by a sudden rise in fluid pressure within the eye after surgery, and damage to the retina caused by infection or retinal detachment. Sudden pressure rises are much less common with the newer v4c ICL used for treating myopic patients. The v4c ICL allows natural fluid flow through the pupil and does not require a bypass drainage hole in the iris. If pressure rises do still occur, it is normally because of incomplete removal of supporting gel – a problem that can be fixed relatively easily with further washout. All patients with high levels of short sight have a higher risk of retinal detachment. This risk is not increased by ICL implantation, which does not involve surgery to the back compartment of the eye. Infection rates after ICL implantation are very low (approximately 1 in 6000).
Complete loss of vision can occur after any operation involving the inside of the eye; but this is rare after ICL implantation. Although fluid pressure rises and infection can occur after Artisan/Verysise PIOL implantation, the risk of problems leading to visual loss generally relates to later complications, particularly corneal clouding. These problems can often be spotted at an early stage and may be partially or completely intercepted by PIOL removal. Annual review with your eye surgeon for life is normally recommended after Artisan/Verysise PIOL implantation, whereas a standard optometric eye health check once a year is sufficient after ICL implantation for which the main long-term risk is cataract formation. Your surgeon will be looking through a microscope to perform the surgery. You will be lying down under a surgical tent with fresh air coming in underneath. A sticky plastic drape covers the skin around the eye and sticks the eyelashes out of the way. Strong pupil dilating drugs are given as drops or a using a pellet placed under the lower eyelid to prepare the eye for surgery. Essential steps in surgery are:
During an office visit one week before surgery, your ophthalmologist will use a laser to create a small opening between the lens and the front chamber of your eye. This allows fluid to pass between the two areas, thereby avoiding the buildup of intraocular pressure following the surgery.
The implantation procedure itself takes about 15 minutes and is performed on an outpatient basis, though you will have to make arrangements for someone to drive you to and from the procedure.
Most patients experience very little discomfort during the ICL implantation. You will undergo treatment while under a light topical or local anesthetic, perhaps with the addition of a mild sedative. Following surgery, you may use prescription eye drops or oral medication. The day after surgery, you will return to your surgeon for a follow-up visit. You also will have follow-up visits one month and six months following the procedure.
Although the ICL requires no special maintenance, you are encouraged to visit your eye doctor annually for check-ups following the procedure.
PIOLs are highly effective at treating both high glasses prescriptions and astigmatism. For most patients, vision after PIOL surgery is similar to vision in contact lenses before surgery without the discomfort and limitations on activity.
You may experience infection, bleeding, or severe inflammation (pain, redness, and decreased vision). These are rare complications that can sometimes lead to permanent loss of vision or loss of the eye. Long-term data are not available. Phakic lenses are a new technology and have only recently been approved by the FDA.
Risks